#EGeneCell 2026 brings together the experts shaping the next generation of AAV, LV, non-viral vector, and cell therapy manufacturing, with a focused agenda dedicated to CMC strategy, process development, quality, analytics, and scalable vector production.
As advanced therapies move rapidly toward late-stage clinical and commercial reality, the summit provides a critical platform to address regulatory expectations, comparability requirements, cost pressures, manufacturing bottlenecks, and evolving analytical standards across the CGT landscape.
Why Attend?
Experience a deep dive into next-wave technologies, new regulatory guidance, and emerging industry standards that are redefining how gene and cell therapies are designed, manufactured, and controlled.#EGeneCell 2026 highlights innovations in:
-
Closed & modular manufacturing platforms
-
Continuous processing and intensified workflows
-
AI/ML-driven analytics and digital CMC
-
High-productivity vector engineering & novel capsids
-
Advanced CQAs, potency assays, and functional release testing
-
Automation & robotics for aseptic CGT operations
This event is designed to equip teams with actionable solutions to scale complex therapies while safeguarding quality, safety, and regulatory compliance.
Industry Trends, Pain Points & Critical Issues
- Regulatory Tightening & Evolving Guidance
New expectations for potency assays, comparability, and raw material control are increasing CMC complexity.
- Manufacturing Scalability & Cost Pressure
Challenges include: